Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome
Rattachement africain : it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Severe cases of COVID-19 present with serious lung inflammation, acute respiratory distress syndrome and multiorgan damage. SARS-CoV-2 infection is associated with high cytokine levels, including interleukin-6 and certain subsets of immune cells, in particular, NK, distinguished according to the cell surface density of CD56. Cytokine levels are inversely correlated with lymphocyte count, therefore cytokine release syndrome may be an impediment to the adaptive immune response against SARS-CoV-2 infection. Canakinumab, a monoclonal antibody targeting IL-1β is under investigation for the treatment of severe SAR-CoV-2 infection. An 85 year old male presenting in our hospital with COVID-19, whose condition was complicated by acute respiratory distress syndrome and cardiac and renal failure (with oliguria) after 25 days of hospitalization, was intubated and received canakinumab for compassionate use. On the next day, diuresis recovered and conditions improved: high IL-6 levels and NK cells expressing CD56bright (associated with cytokine relase) were significantly reduced giving rise to NK CD56dim. Patient died on day 58 with pulmonary bacterial superinfection and persistent SARS-CoV-2 positivity. In conclusion, canakinumab rescued a high risk, very elderly patient, from multiorgan damage complicating COVID-19. It may represent an useful treatment in severe cases.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome
- Date Crossref
- 25/08/2020
- Éditeur
- Frontiers Media SA
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Azienda ospedaliera "Bianchi-Melacrino-Morelli" pays non établi dans la noticeÉtablissement de santé
-
UOSD Terapia Intensiva Post-Operatoria pays non établi dans la noticeInstitution
-
Intensive Care Unit pays non établi dans la noticeInstitution
-
Dipartimento di Microbiologia e Virologia pays non établi dans la noticeInstitution
-
Central Pharmacy pays non établi dans la noticeInstitution
-
UOC Laboratorio Analisi pays non établi dans la noticeInstitution
-
Hematology Unit pays non établi dans la noticeInstitution
Azienda ospedaliera "Bianchi-Melacrino-Morelli", UOSD Terapia Intensiva Post-Operatoria et Intensive Care Unit, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.